Table 1.
Baseline patient demographics.
| IBD * (n = 54) |
Control Group (n = 69) | p Value | ||
|---|---|---|---|---|
| Males, n ξ (%) | 20 (37%) | 26 (37.7%) | 0.9 | |
| Mean age, years ± SD β | 37.3 ± 14.7 | 37.8 ± 15.2 | 0.8 | |
| BMI ¥ (mean Kg/m2 ± SD) | 24.07 ± 4.04 | 23.5 ± 4.01 | 0.4 | |
| Smoking habits | Yes, n (%) | 9 (16.7%) | 10 (14.5%) | 0.8 |
| No/Ex, n (%) | 45 (83.3%) | 59 (85.5%) | 0.1 | |
| Symptoms | Abdominal pain, n (%) | 15 (27.8%) | 19 (27.5%) | 0.4 |
| Diarrhoea, n (%) | 16 (29.6%) | 20 (29%) | 0.6 | |
| Bloating, n (%) | 23 (42.6%) | 30 (43.5%) | 0.3 | |
| Crohn’s disease, n (%) | 22 (40.7%) | |||
| Ulcerative colitis, n (%) | 32 (59.3%) | |||
| Montreal Classification | L1 ° | 16 (72.7%) | ||
| L2 °° | 1 (4.5%) | |||
| L3 °°° | 5 (22.7%) | |||
| L4 °°°° | 0 | |||
| E1 ץ | 11 (34.4%) | |||
| E2 ץץ | 9 (28.1%) | |||
| E3 ץץץ | 12 (37.5%) | |||
| Medications | Mesalamine, n (%) | 42 (77.8%) | ||
| Steroids, n (%) | 3 (5.6%) | |||
| Immunosuppressants, n (%) | 3 (5.6%) | |||
| Biologics, n (%) | 7 (12.9%) | |||
| Antibiotics, n (%) | 2 (3.7%) | |||
| Positive H-BT ¶, n (%) | 35 (64.8%) | 43 (62.3%) | 0.3 | |
| Genetics, n (%) | Wild type | 46 (85.2%) | 60 (87%) | 0.1 |
| CT-22018 | 5 (9.3%) | 4 (5.8%) | 0.8 | |
| AG-13910 | 1 (1.8%) | 4 (5.8%) | 0.3 | |
| CT-22018/AG-13910 | 2 (3.7%) | 1 (1.4%) | 0.6 | |
IBD *, inflammatory bowel disease; n ξ, number; SD β, standard deviation; BMI ¥ body mass index; L1 °, ileal location; L2 °°, colic location; L3 °°°, ileocolic location; L4 °°°°, ileocolic location; E1 ץ, proctitis; E2 ץץ, left-sided colitis; E3 ץץץ, extensive colitis; H-BT ¶, hydrogen-breath test.